Niagen Bioscience price target raised to $23 from $10 at Roth Capital

Roth Capital raised the firm’s price target on Niagen Bioscience (NAGE) to $23 from $10 and keeps a Buy rating on the shares. The stock has been “very strong” over the last year and continues to offer significant upside potential from the expansion of its addressable markets pending the outcome of a number of trials and studies currently in process, the analyst tells investors in a research note. Roth further cites the continued strong growth in sales of TruNiagen, the company’s core product, its immunity from the impact of tariffs, and encouraging progress being made in several new initiatives, include Niagen Plus, which began rolling out to clinics in late 2024.